Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment

NCT ID: NCT07034469

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-20

Study Completion Date

2029-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TITLE: RCT of air tamponade versus fluorinated gas tamponade for rhegmatogenous retinal detachment DESIGN: Non-inferiority RCT of 150 patients from 10 UK centres AIMS: To assess whether air tamponade is non inferior to gas tamponade for the repair of RRD treated with vitrectomy.

PRIMARY OUTCOME MEASURE: Primary anatomical success with single operation at 24 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY OBJECTIVES To assess whether air tamponade is non inferior to gas tamponade for the repair of RRD with superior breaks treated with vitrectomy and to assess how cost-effective air tamponade is compared to gas tamponade BACKGROUND Rhegmatogenous retinal detachment (RRD) is the most common form of RD developing when there is a retinal 'break' that allows the ingress of fluid from the vitreous cavity into the subretinal space. There are three main current options for the management of RRD, namely pneumoretinopexy, scleral buckling and vitrectomy (PPV). Vitrectomy is currently performed for the majority of RRDs in the UK. Tamponade in PPV is usually performed by complete filling of the vitreous cavity with fluorinated gases diluted in air at iso-volumetric concentrations which do not expand (e.g., 20% SF6 or 14% C3F8).

RATIONALE FOR CURRENT STUDY The use of air instead of fluorinated gases in primary RRD treated with vitrectomy has been the subject of much debate recently. Air being non expansile and short lived it offers the prospect of quicker rehabilitation and less risk and avoids the use of environmentally damaging fluorinated gases. The question of whether air offers equivalence to gas for uncomplicated RRD with mainly superior breaks has not been adequately answered, as reviewed in a recent systematic review and meta-analysis where the certainty of evidence was judged very low. This type of detachment is the commonest at approximately 60% of the cases in the BEAVRS database and representing approximately 4,800 RRD in the UK per annum. There has been significant interest in air recently with the announcement of the European chemical agencies proposed ban on fluorinated gases.

There are several potential benefits of using air over gas to repair detached retinas.

1. Speedier visual recovery, which may mean earlier return to work or normal activities.
2. Avoiding expansile fluorinated gas-related complications such as raised eye pressure, reducing the number of post-operative visits and medications needed after surgery.
3. Fewer restrictions after surgery (able to fly and drive sooner and shorter restrictions on anaesthetic agents)
4. Decreased environmental impact by reducing greenhouse gas use. If air was proven to be non-inferior to gas, then patients with RRD treated by vitrectomy would likely prefer it STUDY DESIGN RCT of people presenting with uncomplicated RRD treated with vitrectomy comparing air to gas tamponade.

Participants will be randomised 1:1 between air tamponade and gas tamponade. Randomisation will be performed using a secure web-based randomisation system at the time of surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Detachment Rhegmatogenous

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

retinal detachment gas tamponade air

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

one arm will have standard of care gas tamponade, the study arm will have air tamponade
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sterile air tamponade

use of sterile air in place of fluorinated gases as a tamponade agent for rhegmatogenous retinal detachment vitrectomy surgery

Group Type EXPERIMENTAL

air

Intervention Type PROCEDURE

use of sterile air as a tamponade

Fluorinated gas tamponade

use of fluorinated gas (SF6, C2F6 or C3F8) as a tamponade agent for rhegmatogenous retinal detachment treated with vitrectomy

Group Type ACTIVE_COMPARATOR

Gas SF6 (Sulfur Hexafluoride) and others

Intervention Type PROCEDURE

use of fluorinated gases such as SF6, C2F6 or C3F8 as a tamponade agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

air

use of sterile air as a tamponade

Intervention Type PROCEDURE

Gas SF6 (Sulfur Hexafluoride) and others

use of fluorinated gases such as SF6, C2F6 or C3F8 as a tamponade agent

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary uncomplicated RRD undergoing vitrectomy.
* Phakic and pseudophakic eyes
* Retinal breaks superiorly between 3 and 9 o'clock, and that are separated by less than 4 clock hours.

Exclusion Criteria

* Absence of PVD
* Age 40 years or younger
* PVR grade C or above
* Aphakia or anterior chamber lens
* Retinal breaks greater than 1 clock hour in size
* Retinal breaks that exist below 3 and 9 o'clock on both the nasal and temporal sides.
* Retinal breaks at or posterior to the vessel arcades
* Current or previous -6D myopia or greater (or axial length \>26millimetres (mm))
* Chronic RRD judged by the presence of subretinal bands and other signs of -chronicity or by history of visual loss for \>28 days.
* Significant inflammation, choroidal detachments, hypotony (\<6 millimetres of mercury (mmHg) preop)
* Previous open-globe injury, or endophthalmitis
* Current or previous posterior uveitis or choroiditis
* Any intraocular surgical procedure within 4 weeks other than laser/cryotherapy
* Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Liverpool University Hospitals NHS Foundation Trust

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rumana N Hussain, MBBS, FRCOph

Role: PRINCIPAL_INVESTIGATOR

Liverpool University Hospitals NHS Foundation Trust UK

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rumana N Hussain, MBBS, FRCOph

Role: CONTACT

Phone: 01517063986

Email: [email protected]

Darina Koneva

Role: CONTACT

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LHS0250

Identifier Type: -

Identifier Source: org_study_id